Golimumab, a human monoclonal antibody to tumour necrosis factor (TNF)-α that is administered subcutaneously every 4 weeks, is approved for treating active ankylosing spondylitis (AS). We previously reported results of the double-blind, randomised, placebo-controlled, Phase 3 GO-RAISE study, in which golimumab was evaluated in patients with active AS, through week 24[@R1] and week 104[@R2] and now report findings through the completion of the 5-year GO-RAISE trial.

Patients and methods {#s1}
====================

Details of GO-RAISE patient eligibility criteria and study design have been reported[@R1] and are summarised in the online supplement. Details of analyses specific to this 5-year report are also provided in the online supplement.[@R3]

Results {#s2}
=======

Patient disposition/characteristics and concomitant medications {#s2a}
---------------------------------------------------------------

Among the 356 randomised patients, 355 received study treatment ([figure 1](#ANNRHEUMDIS2014205862F1){ref-type="fig"}). Baseline patient and disease characteristics,[@R1] as well as patient disposition through week 24[@R1] and week 104,[@R2] have been reported.

![Patient disposition through week 268.](annrheumdis-2014-205862f01){#ANNRHEUMDIS2014205862F1}

At week 16, 41 of 78 (52.6%) and 25 of 137 (18.2%) patients in Groups 1 and 2, respectively, had \<20% improvement in total back pain and morning stiffness and entered early escape. Among the 355 treated patients, 101 (28.5%) discontinued study agent through week 252 ([figure 1](#ANNRHEUMDIS2014205862F1){ref-type="fig"}). Among patients who discontinued study agent due to adverse events (AEs), being lost to follow-up, or due to 'other' reasons, 51% achieved an Assessment in SpondyloArthritis international Society criteria for 20% improvement (ASAS20) response at the visit preceding discontinuation, versus 15% of patients who discontinued due to unsatisfactory therapeutic effect.

The proportion of patients using non-steroidal anti-inflammatory drugs declined from baseline to week 268 from 90% to 74% while that using disease-modifying antirheumatic drugs was relatively stable (32% to 36%) during the study.

Efficacy {#s2b}
--------

### Assessment in SpondyloArthritis international Society (ASAS) responses {#s2b1}

Results of intent-to-treat (ITT) analyses indicated that 220/356 (61.8%) and 166/356 (46.6%) patients achieved ASAS20 response and/or ≥40% improvement (ASAS40) improvement, respectively, at week 24. At week 256, 235/356 (66.0%; 95% CI 61.1% to 70.9%) and 203/356 (57.0%; 95% CI 51.9% to 62.1%) patients achieved ASAS20 and/or ASAS40 response, respectively ([figure 2](#ANNRHEUMDIS2014205862F2){ref-type="fig"}A, B). ASAS partial remission (value \<2 in each ASAS domain) was achieved by 121/356 (34.0%; 95% CI 29.1% to 38.9%) patients treated with golimumab at week 256 ([figure 2](#ANNRHEUMDIS2014205862F2){ref-type="fig"}C). Response rates were consistent, albeit somewhat higher, when assessed using observed data among patients who did not discontinue study participation by week 24 (see online supplementary figure S1A--C).

![The proportions of patients in ASAS20 response (A), ASAS40 response (B), and/or ASAS partial remission (C) through week 256 based on intent-to-treat analyses. The placebo-controlled study period ended at week 24, but study participants and investigators remained blinded to the golimumab dose (50 mg or 100 mg) through week 100. During the long-term extension, which started with the week-104 golimumab injection, the investigator could increase or decrease the golimumab dose. ASAS20/40, ≥20%/40% improvement in the Assessment of SpondyloArthritis international Society (ASAS) criteria.](annrheumdis-2014-205862f02){#ANNRHEUMDIS2014205862F2}

Based on observed data, 54 patients escalated the golimumab dose from 50 mg to 100 mg during the trial. While 21 (38.9%) and 16 (29.6%) of these patients, respectively, achieved an ASAS20 or ASAS40 response before dose escalation, 33 and 38 patients, respectively, had not. Among these latter patients, 60.6% (20/33) achieved ASAS20 and 44.7% (17/38) achieved ASAS40 responses following ≥2 consecutive doses of golimumab 100 mg. Additional clinical findings are reported in the online supplement.

### Health-related quality of life (HRQoL) {#s2b2}

Mean changes from baseline in the physical component summary and mental component summary scores of the 36-item Short Form health survey indicated improvements in patients' HRQoL were sustained with up to 5 years of golimumab treatment (see online supplementary table S1). When assessed using ITT analyses, 93/356 (26.1%; 95% CI 21.5% to 30.7%) and 180/356 (50.6%; 95% CI 45.4% to 55.8%) had achieved 36-item Short Form health survey physical component summary and mental component summary scores ≥50, respectively, at week 256 (see online supplementary table S1). Findings were consistent with observed data (data not shown).

Antibodies to golimumab {#s2c}
-----------------------

Antibody-to-golimumab findings are reported in the online supplement.

Safety {#s2d}
------

Safety results through week 24[@R1] and week 104[@R2] were previously reported. Reported AEs from baseline through week 268 are summarised in [table 1](#ANNRHEUMDIS2014205862TB1){ref-type="table"} for patients who received ≥1 dose of golimumab through the first use of commercial biologics.

###### 

Summary of AEs through week 268

  -----------------------------------------------------------------------------------------------------------------------------
                                                  GLM 50 mg only    GLM 50 mg and 100 mg   GLM 100 mg only   All GLM patients
  ----------------------------------------------- ----------------- ---------------------- ----------------- ------------------
  No. of patients                                 158               77                     118               353

  Mean weeks of follow-up                         207.6             232.2                  213.0             214.8

  Pts with AE(s)                                  153 (96.8%)       76 (98.7%)             115 (97.5%)       344 (97.5%)

  Pts who died                                    1 (0.6%)          0 (0.0%)               0 (0.0%)          1 (0.3%)

   Incidence/100 pt-yrs\*\                        0.16\             0.00\                  0.00\             0.07\
   (Exact 95% CI)                                 (0.00 to 0.88)    (0.00 to 0.87)         (0.00 to 0.62)    (0.00 to 0.38)

  Pts with serious AE(s)                          27 (17.1%)        19 (24.7%)             26 (22.0%)        72 (20.4%)

  Pts who discontinued study agent due to AE(s)   12 (7.6%)         6 (7.8%)               14 (11.9%)        32 (9.1%)

  Pts with malignancy†                            1 (0.6%)          1 (1.3%)               1 (0.8%)          3 (0.8%)

   Incidence/100 pt-yrs\                          0.16\             0.29\                  0.21\             0.21\
   (Exact 95% CI)                                 (0.00 to 0.88)    (0.01 to 1.63)         (0.01 to 1.16)    (0.04 to 0.60)

   SIR---observed/SEER\                           0.58\             0.00\                  0.00\             0.21\
   (Exact 95% CI)                                 (0.01 to 3.21)    (0.00 to 1.77)         (0.00 to 2.37)    (0.01 to 1.19)

   *Lymphoma*‡                                    1 (0.6%)          0 (0.0%)               0 (0.0%)          1 (0.3%)

   Incidence/100 pt-yrs\                          0.16\             0.00\                  0.00\             0.07\
   (Exact 95% CI)                                 (0.00 to 0.88)    (0.00 to 0.87)         (0.00 to 0.62)    (0.00 to 0.38)

   SIR---observed/SEER\                           9.67\             0.00\                  0.00\             3.80\
   (Exact 95% CI)                                 (0.24 to 53.90)   (0.00 to 35.60)        (0.00 to 39.68)   (0.10 to 21.18)

   *NMSC*§                                        0 (0.0%)          1 (1.3%)               1 (0.8%)          2 (0.6%)

   Incidence/100 pt-yrs\                          0.00\             0.29\                  0.21\             0.14\
   (Exact 95% CI)                                 (0.00 to 0.47)    (0.01 to 1.63)         (0.01 to 1.16)    (0.02 to 0.50)

   *Other malignancies*¶                          1 (0.6%)          0 (0.0%)               0 (0.0%)          1 (0.3%)

   Incidence/100 pt-yrs\                          0.16\             0.00\                  0.00\             0.07\
   (Exact 95% CI)                                 (0.00 to 0.88)    (0.00 to 0.87)         (0.00 to 0.62)    (0.00 to 0.38)

   SIR---observed/SEER\                           0.61\             0.00\                  0.00\             0.22\
   (Exact 95% CI)                                 (0.02 to 3.39)    (0.00 to 1.85)         (0.00 to 2.52)    (0.01 to 1.25)

  Pts with serious infection(s)                   6 (3.8%)          8 (10.4%)              7 (5.9%)          21 (5.9%)

   Incidence/100 pt-yrs\*\*\                      1.27\             3.49\                  2.28\             2.13\
   (Exact 95% CI)                                 (0.55 to 2.50)    (1.80 to 6.10)         (1.14 to 4.07)    (1.44 to 3.02)

  Pts with injection-site reaction(s)             17 (10.8%)        13 (16.9%)             13 (11.0%)        43 (12.2%)
  -----------------------------------------------------------------------------------------------------------------------------

Data presented are n (%) unless indicated otherwise.

\*Incidence/100 pt-yrs (Exact 95% CI) of death for placebo through week 24=0.00 (0.00 to 10.42).

†Incidence/100 pt-yrs (Exact 95% CI) of all malignancies for placebo through week 24=3.50 (0.09 to 19.48); SIR (Exact 95% CI)=0.00 (0.00 to 33.37).

‡Incidence/100 pt-yrs (Exact 95% CI) of lymphoma for placebo through week 24=0.00 (0.00 to 10.42); SIR (Exact 95% CI)=0.00 (0.00 to 582.38).

§Incidence/100 pt-yrs (Exact 95% CI) of NMSC for placebo through week 24=3.50 (0.09 to 19.48).

¶Incidence/100 pt-yrs (Exact 95% CI) of other malignancies for placebo through week 24=0.00 (0.00 to 10.42); SIR (Exact 95% CI)=0.00 (0.00 to 35.31).

\*\*Incidence/100 pt-yrs (Exact 95% CI) of serious infections for placebo through week 24=3.48 (0.09 to 19.39).

AE, adverse event; GLM, golimumab; NMSC, non-melanoma skin cancer; no., number; pts, patients; pt-yrs, patient-years; SEER, Surveillance, Epidemiology and End Results database; SIR, standardised incidence ratio.

Through week 268, serious AEs were reported for 72 (20.4%) patients treated with golimumab ([table 1](#ANNRHEUMDIS2014205862TB1){ref-type="table"}), most commonly osteoarthritis requiring hospitalisation (2.0%), pneumonia (1.1%), worsening of AS (1.1%), and depression (1.1%). No increases in serious AEs were observed in successive years of golimumab treatment (see online supplementary table S2).

One (0.3%) patient, randomised to receive golimumab 50 mg, died from pancreatic cancer. This patient had also developed lymphoma after 3 years in the study and was receiving chemotherapy when the pancreatic cancer was discovered. The overall incidence of death for patients treated with golimumab was 0.07/100 patient-years (95% CI 0.00 to 0.38), with no difference observed between doses ([table 1](#ANNRHEUMDIS2014205862TB1){ref-type="table"}). In addition to the malignancies in one patient described above, two patients treated with golimumab had non-melanoma skin cancer (NMSC) through week 268, including one (1.3%) patient each receiving golimumab 50 mg and 100 mg and golimumab 100 mg only. For lymphoma, NMSC, other malignancies and all malignancies, the incidences per 100 patient-years did not appear to be dose-related ([table 1](#ANNRHEUMDIS2014205862TB1){ref-type="table"}). Similarly, the incidences of malignancies other than NMSC (excluded from the Surveillance, Epidemiology, and End Results database) were not elevated relative to those expected in the USA population ([table 1](#ANNRHEUMDIS2014205862TB1){ref-type="table"}). No overall increase in the incidence of malignancies was observed in successive years of golimumab treatment (see online supplementary table S2).

Serious infections were reported for 5.9% (21/353) of patients treated with golimumab through week 268. Pneumonia (four (1.1%) patients) was the only serious infection reported by more than one patient. The incidence of serious infections among patients receiving golimumab 100 mg appeared higher than for patients receiving only golimumab 50 mg ([table 1](#ANNRHEUMDIS2014205862TB1){ref-type="table"}). No increase in serious infections was observed, however, in successive years of golimumab treatment (see online supplementary table S2).

Discussion {#s3}
==========

Improvements in signs/symptoms, physical function, range of motion and HRQoL achieved at week 24[@R1] and sustained through week 104[@R2] of GO-RAISE were also sustained with up to 5 years of golimumab treatment of patients with AS. While findings were generally similar between the golimumab doses, this is the first report to assess the effects of a dose increase in patients with AS who had inadequate response to golimumab 50 mg. When investigators were allowed to increase the dose in consultation with their patients for lack of efficacy, 61% of patients gained ASAS20 response. While the golimumab dose approved for the treatment of active AS is 50 mg, this is an important finding that reflects a scenario likely to be encountered in clinical practice. Results of the recently published certolizumab trial in axial spondyloarthritis, which compared the same cumulative dose given at two different dosing intervals (200 mg every 2 weeks and 400 mg every 4 weeks), indicated very similar efficacy.[@R13] Thus, to our knowledge, GO-RAISE is the only large prospective trial of a TNF-inhibitor in AS comparing two different doses and showing a dose response in patients who have inadequate response to the lower dose. Similar findings have been reported in patients with rheumatoid arthritis.[@R14]

Approximately a fifth of the 255 patients who participated in the long-term extension did not achieve an ASAS20 response at 5 years, yet they continued to receive golimumab and completed the trial, which is consistent with results observed through \>3 years of etanercept[@R15] and 5 years of adalimumab[@R16] in patients with AS. Thus, while ASAS20 response is a validated composite measure of patient outcome, it may not include all aspects of improvement important to patients. Also, while 20% improvement in symptoms is the lowest level acceptable to a clinician to indicate efficacy, an individual patient may consider a different level of improvement acceptable to continue that therapy. Indeed, we determined that even though these patients were deriving \<20% relief in their night-time pain, overall back pain, and sleep improvement, their cumulative improvement was enough for them to elect study continuation. Since treatment with TNF-inhibitors can be costly, recommendations on the expected minimal therapeutic response for such agents have been published by independent organisations such as ASAS. These recommendations include assessment of response based on one outcome measure, plus expert opinion, for continuation of treatment. Our results, as well as those observed with other agents, suggest that there is apparent benefit, including improved performance-based physical function in ASAS20 non-responders, experienced by patients that is not captured by a single measure.[@R15] Hence, other tertiary end points or patient-reported outcomes should be considered in future research of treatment persistence.

The golimumab safety profile through week 268 was consistent with those previously reported.[@R1] [@R2] Importantly, no increases in serious AEs, malignancies, serious infection or injection-site reactions were observed in successive years of golimumab treatment.

While efficacy analyses were performed using a conservative ITT approach, and consistency was observed between the ITT and observed data analyses, the findings reported here remain limited by several factors. It is important to note that no patients received placebo, and thus there is no control group, after week 24. Also, the study was blinded through the week 100 database lock, but open label from that point forward. Changes to the golimumab dose from 50 mg to 100 mg or from 100 mg to 50 mg during the study extension were at the discretion of the investigator. Thus, since dose escalation was uncontrolled, conclusions related to dose change are limited. Additionally, while long-term efficacy and safety have been observed over 5 years, long-term effectiveness in the context of cost-effectiveness requires evaluation using real-world data in patients with AS treated with golimumab.

Taken together, results reported here indicate that clinical improvements observed in patients with AS treated with golimumab through week 24 were sustained through up to 5 years of treatment. Importantly, no new safety signals were detected, and the golimumab benefit-risk profile remains positive.

Supplementary Material
======================
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